Enfuvirtide (Fuzeon)

Published March 17, 2003; Updated September 21, 2007
Susa Coffey, MD
Selected Reference
8. Trottier  B, Walmsley  S, Reynes  J, Piliero  P, O'Hearn  M, Nelson  M, Montaner  J, Lazzarin  A, Lalezari  J, Katlama  C, Henry  K, Cooper  D, Clotet  B, Arastéh  K, Delfraissy  JF, Stellbrink  HJ, Lange  J, Kuritzkes  D, Eron  JJ, Cohen  C, Kinchelow  T, Bertasso  A, Labriola-Tompkins  E, Shikhman  A, Atkins  B, Bourdeau  L, Natale  C, Hughes  F, Chung  J, Guimaraes  D, Drobnes  C, Bader-Weder  S, Demasi  R, Smiley  L, Salgo  MP.
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005 Dec;40(4):413-21
[PubMed ID: 16280695]
BACKGROUND: Antiretroviral tolerability is a critical factor contributing to treatment outcome. The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients. METHODS: A total of 997 patients were randomized at a 2:1 ratio to an optimized background antiretroviral regimen plus enfuvirtide (n = 663) or an optimized background regimen alone (control group; n = 334). Control patients could switch to enfuvirtide on virologic failure. RESULTS: In total, 26.5% of patients randomized to enfuvirtide and 36.6% to the control group discontinued study treatment before week 48; the percentage of patients withdrawn for safety reasons (including adverse events [AEs], deaths, and laboratory abnormalities) was 14.0% in the enfuvirtide group and 11.6% in the control group. Injection site reactions (ISRs) occurred in 98% of enfuvirtide patients and led to treatment discontinuation in 4.4%. Treatment-related (defined as possibly, probably, or remotely) AE rates per 100 patient-years were lower with enfuvirtide (96.2) than in the control group (149.9); diarrhea, nausea, and fatigue, the most frequently reported AEs, were significantly less frequent with enfuvirtide than in the control group. Pneumonia was significantly more frequent in patients treated with enfuvirtide (6.7 vs. 0.6 events per 100 patient-years), although the incidence was within expected ranges for this population. Lymphadenopathy was also higher in enfuvirtide-treated patients (7.1 vs. 1.2 events per 100 patient-years) for control patients. CONCLUSION: The addition of enfuvirtide to an optimized background regimen does not exacerbate AEs commonly associated with antiretrovirals. ISRs limited treatment in <5% of patients.